Literature DB >> 33287242

Update on the Management of Breast Cancer during Pregnancy.

Francesca Poggio1, Marco Tagliamento2,3, Chiara Pirrone2,3, Davide Soldato2,3, Benedetta Conte2,3, Chiara Molinelli2,3, Maurizio Cosso4, Piero Fregatti5,6, Lucia Del Mastro1,3, Matteo Lambertini3,7.   

Abstract

The diagnosis of breast cancer during pregnancy represents a challenging situation for the patient, her caregivers and physicians. Pregnancy adds complexity to oncological treatment planning, as many therapies can be potentially dangerous to the fetus. Therefore, a multidisciplinary approach is needed to offer a proper care for obtaining the best possible outcomes for the mother and the future child. Breast surgery is feasible throughout the pregnancy while radiotherapy should be postponed after delivery. Administration of chemotherapy is considered safe and can be given during the second and third trimesters, while it is contraindicated in the first trimester due to the high risk of fetal malformations. Endocrine therapy and targeted agents are not recommended during the whole pregnancy period; however, limited data are available on the use of the majority of new anticancer drugs in this context. The aim of the current review is to provide an update on the current state of art about the management of women diagnosed with breast cancer during pregnancy.

Entities:  

Keywords:  breast cancer; chemotherapy; endocrine therapy; immunotherapy; pregnancy; pregnancy during breast cancer; radiotherapy; surgery; targeted therapy

Year:  2020        PMID: 33287242     DOI: 10.3390/cancers12123616

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  2 in total

Review 1.  Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy.

Authors:  Silvia Triarico; Serena Rivetti; Michele Antonio Capozza; Alberto Romano; Palma Maurizi; Stefano Mastrangelo; Giorgio Attinà; Antonio Ruggiero
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

2.  Editorial: Breast Cancer in Young Women: Dedicated Research Efforts Are Needed.

Authors:  Matteo Lambertini; Hee Jeong Kim; Philip Poorvu
Journal:  Front Oncol       Date:  2022-06-01       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.